PRESS RELEASE

Vesalio announces oversubscribed class A financing

May 19, 2022

Nashville, TN – (May 18, 2022) – Vesalio, an emerging leader in improving outcomes in patients with vascular occlusion, is proud to announce it has oversubscribed its Class A financing round. Solas BioVentures led the investment with participation by new and existing investors, including the recent addition of Orlando Health Ventures.

With an expanding customer base established in Europe, Vesalio will use this funding to enter the U.S. market by executing FDA clearances, adding key personnel, developing support infrastructure, expanding its product portfolio, and completing its cardiology clinical study.

“This financing round advances Vesalio’s mission to improve outcomes in patients suffering a stroke and other conditions created by blood clots,” said Mike Kujak, Vesalio Board Chairman. “As the medical field continues to evolve in treating vascular occlusion, physicians are seeking a device that effectively removes all types of blood clots to improve patient outcomes by reducing the time it takes to restore blood flow. This oversubscribed round of funding allows us to complete the development and introduction of new technology and accelerate the market growth of Vesalio’s proprietary platforms.”

Vesalio is also pleased to announce a new addition to its board of directors: Bobby Helmedag, the managing director of Orlando Health Ventures. “We are excited to be Vesalio investors,” expressed Mr. Helmedag. “Their NeVa and enVast platforms have shown extremely promising results, and we look forward to supporting them as they scale global markets and enter the U.S. market. And importantly, CEO Steve Rybka has assembled a top-notch team prepared to drive market penetration through Vesalio’s next wave of growth.”

 

About Vesalio

Founded in 2013, Vesalio is a privately held medical device company committed to advancing patient care in vascular occlusion by providing physicians superior technology designed to improve clinical outcomes. The company’s proprietary NeVa™ platform was designed to consistently achieve first-pass recanalization in acute ischemic stroke by effectively removing all types of neurovascular clots from patient anatomy.
For more information, please visit vesalio.com .

 

About Solas BioVentures

Solas BioVentures is a venture capital firm that invests exclusively in the life science industry, focusing on early and development stage Biotech and MedTech companies advancing impactful, disruptive technologies. Headquartered in Chattanooga, Tennessee, its coverage is global. For more information, visit solasbio.com.

 

About Orlando Health Ventures

Orlando Health Ventures  is the venture arm of  Orlando Health , a not-for-profit healthcare organization with $8 billion of assets under management that serves the southeastern United States and is headquartered in Orlando, Florida. Orlando Health is a 3,200-bed system that includes: 10 award-winning hospitals, 9 hospital-based ERs, 7 freestanding emergency rooms, rehabilitation services, cancer and heart institutes, imaging and laboratory services, wound care centers, physician offices for adults and pediatrics, skilled nursing facilities, an in-patient behavioral health facility, home healthcare services in partnership with LHC Group, and urgent care centers in partnership with FastMed Urgent Care. More than 4,200 physicians representing more than 100 medical specialties and subspecialties have privileges across the Orlando Health system, which employs more than 23,000 team members.

More News

INTERVIEW

Only one year old, but with an expanding international presence: Meet Vesalio!

INTERVIEW

Meet Perflow: A new startup with a novel technology in “real time”

INTERVIEW

Discover Stryker’s new SKILL™ initiative: Stroke Knowledge Initiatives for Learning and Leadership

INTERVIEW

Cerenovus: raising the bar for clot research

INTERVIEW

SIM&CURE’s proven technology and AI designed “by and for” the specialist